{"id":6227,"date":"2018-07-23T16:18:33","date_gmt":"2018-07-23T20:18:33","guid":{"rendered":"https:\/\/www.silverlaw.com\/blog\/?p=6227"},"modified":"2018-07-23T16:18:33","modified_gmt":"2018-07-23T20:18:33","slug":"recro-pharmas-investment-banker-and-underwriter-was-aegis-financial-in-recro-pharmas-2014-ipo","status":"publish","type":"post","link":"https:\/\/www.silverlaw.com\/blog\/recro-pharmas-investment-banker-and-underwriter-was-aegis-financial-in-recro-pharmas-2014-ipo\/","title":{"rendered":"Recro Pharma\u2019s Investment Banker and Underwriter was Aegis Financial in Recro Pharma\u2019s 2014 IPO"},"content":{"rendered":"

Recro is a specialty pharmaceutical company that develops non-opioid therapeutics for the treatment of pain in the post-operative setting. Recro offers its products to the medical industry. The Company\u2019s lead product is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor (\u201cIV meloxicam\u201d) to be used for the management of moderate to severe pain.<\/p>\n

\"iStock-509557490-300x200\"
\nRecro Pharma is the subject of a class action complaint that alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company\u2019s business, operational and compliance policies. Specifically, Defendants made false and\/or misleading statements and\/or failed to disclose that: (i) IV meloxicam lacked supporting clinical data to show sufficient clinical benefits to receive U.S. Food and Drug Administration (\u201cFDA\u201d) approval; and (ii) as a result, Recro\u2019s public statements were materially false and misleading at all relevant times.<\/p>\n

On May 24, 2018, Recro announced that the FDA had declined to approve Recro’s New Drug Application (\u201cNDA\u201d) for IV meloxicam. In its Complete Response Letter, the FDA stated that the drug’s analgesic effects did not meet FDA expectations and raised questions related to chemistry, manufacturing and controls data.<\/p>\n

Continue reading \u203a<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

Recro is a specialty pharmaceutical company that develops non-opioid therapeutics for the treatment of pain in the post-operative setting. Recro offers its products to the medical industry. The Company\u2019s lead product is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor (\u201cIV meloxicam\u201d) to be used for the management of moderate to severe […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[602,590],"tags":[790,954,955,956],"class_list":["post-6227","post","type-post","status-publish","format-standard","hentry","category-class-action","category-misrepresentation-and-omission-of-material-facts","tag-aegis-financial","tag-recro-pharma","tag-recro-pharma-class-action","tag-scott-silver-recro-pharma"],"yoast_head":"\nRecro Pharma\u2019s Investment Banker and Underwriter was Aegis Financial in Recro Pharma\u2019s 2014 IPO — Securities Arbitration Lawyers Blog — July 23, 2018<\/title>\n<meta name=\"description\" content=\"Recro is a specialty pharmaceutical company that develops non-opioid therapeutics for the treatment of pain in the post-operative setting. Recro offers — July 23, 2018\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.silverlaw.com\/blog\/recro-pharmas-investment-banker-and-underwriter-was-aegis-financial-in-recro-pharmas-2014-ipo\/\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Recro Pharma\u2019s Investment Banker and Underwriter was Aegis Financial in Recro Pharma\u2019s 2014 IPO — Securities Arbitration Lawyers Blog — July 23, 2018\" \/>\n<meta name=\"twitter:description\" content=\"Recro is a specialty pharmaceutical company that develops non-opioid therapeutics for the treatment of pain in the post-operative setting. Recro offers — July 23, 2018\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/www.silverlaw.com\/blog\/wp-content\/uploads\/2017\/07\/iStock-509557490.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Silver Law Group\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Recro Pharma\u2019s Investment Banker and Underwriter was Aegis Financial in Recro Pharma\u2019s 2014 IPO — Securities Arbitration Lawyers Blog — July 23, 2018","description":"Recro is a specialty pharmaceutical company that develops non-opioid therapeutics for the treatment of pain in the post-operative setting. Recro offers — July 23, 2018","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.silverlaw.com\/blog\/recro-pharmas-investment-banker-and-underwriter-was-aegis-financial-in-recro-pharmas-2014-ipo\/","twitter_card":"summary_large_image","twitter_title":"Recro Pharma\u2019s Investment Banker and Underwriter was Aegis Financial in Recro Pharma\u2019s 2014 IPO — Securities Arbitration Lawyers Blog — July 23, 2018","twitter_description":"Recro is a specialty pharmaceutical company that develops non-opioid therapeutics for the treatment of pain in the post-operative setting. Recro offers — July 23, 2018","twitter_image":"https:\/\/www.silverlaw.com\/blog\/wp-content\/uploads\/2017\/07\/iStock-509557490.jpg","twitter_misc":{"Written by":"Silver Law Group","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.silverlaw.com\/blog\/recro-pharmas-investment-banker-and-underwriter-was-aegis-financial-in-recro-pharmas-2014-ipo\/","url":"https:\/\/www.silverlaw.com\/blog\/recro-pharmas-investment-banker-and-underwriter-was-aegis-financial-in-recro-pharmas-2014-ipo\/","name":"Recro Pharma\u2019s Investment Banker and Underwriter was Aegis Financial in Recro Pharma\u2019s 2014 IPO — Securities Arbitration Lawyers Blog — July 23, 2018","isPartOf":{"@id":"https:\/\/www.silverlaw.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.silverlaw.com\/blog\/recro-pharmas-investment-banker-and-underwriter-was-aegis-financial-in-recro-pharmas-2014-ipo\/#primaryimage"},"image":{"@id":"https:\/\/www.silverlaw.com\/blog\/recro-pharmas-investment-banker-and-underwriter-was-aegis-financial-in-recro-pharmas-2014-ipo\/#primaryimage"},"thumbnailUrl":"https:\/\/www.silverlaw.com\/blog\/wp-content\/uploads\/2017\/07\/iStock-509557490-300x200.jpg","datePublished":"2018-07-23T20:18:33+00:00","author":{"@id":"https:\/\/www.silverlaw.com\/blog\/#\/schema\/person\/de64d999508b1ad10d608a99f0d2e752"},"description":"Recro is a specialty pharmaceutical company that develops non-opioid therapeutics for the treatment of pain in the post-operative setting. Recro offers — July 23, 2018","breadcrumb":{"@id":"https:\/\/www.silverlaw.com\/blog\/recro-pharmas-investment-banker-and-underwriter-was-aegis-financial-in-recro-pharmas-2014-ipo\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.silverlaw.com\/blog\/recro-pharmas-investment-banker-and-underwriter-was-aegis-financial-in-recro-pharmas-2014-ipo\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.silverlaw.com\/blog\/recro-pharmas-investment-banker-and-underwriter-was-aegis-financial-in-recro-pharmas-2014-ipo\/#primaryimage","url":"https:\/\/www.silverlaw.com\/blog\/wp-content\/uploads\/2017\/07\/iStock-509557490.jpg","contentUrl":"https:\/\/www.silverlaw.com\/blog\/wp-content\/uploads\/2017\/07\/iStock-509557490.jpg","width":1255,"height":836,"caption":"Judge gavel, scales of justice and law books in court"},{"@type":"BreadcrumbList","@id":"https:\/\/www.silverlaw.com\/blog\/recro-pharmas-investment-banker-and-underwriter-was-aegis-financial-in-recro-pharmas-2014-ipo\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.silverlaw.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Recro Pharma\u2019s Investment Banker and Underwriter was Aegis Financial in Recro Pharma\u2019s 2014 IPO"}]},{"@type":"WebSite","@id":"https:\/\/www.silverlaw.com\/blog\/#website","url":"https:\/\/www.silverlaw.com\/blog\/","name":"Securities Arbitration Lawyers Blog","description":"Published by Securities Arbitration Lawyers \u2014 Silver Law Group","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.silverlaw.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.silverlaw.com\/blog\/#\/schema\/person\/de64d999508b1ad10d608a99f0d2e752","name":"Silver Law Group","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.silverlaw.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9eb0a691642ae95c68ee1c45b5f50f35bae76a41f3d9f861c7bfd40c87661746?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9eb0a691642ae95c68ee1c45b5f50f35bae76a41f3d9f861c7bfd40c87661746?s=96&d=mm&r=g","caption":"Silver Law Group"}}]}},"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/posts\/6227","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/comments?post=6227"}],"version-history":[{"count":2,"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/posts\/6227\/revisions"}],"predecessor-version":[{"id":6229,"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/posts\/6227\/revisions\/6229"}],"wp:attachment":[{"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/media?parent=6227"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/categories?post=6227"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.silverlaw.com\/blog\/wp-json\/wp\/v2\/tags?post=6227"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}